split-banner-image

IBCSG IX

Closed

IBCSG IX

BCT Study Chair:

John Forbes

Adjuvant therapy in node negative postmenopausal patients with operable breast cancer.

international

1385

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

330

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

20

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

IBCSG IX PUBLICATIONS

2020

DNA methylation markers predict recurrence-free interval in triple-negative breast cancer.

Fackler MJ, Cho S, Cope L, Gabrielson E, Visvanathan K, Wilsbach K, Meir-Levi D, Lynch C.F., Marks J, Geradts J, Regan MM, Viale G, Wolff AC, Sukumar S, Umbricht CB. npj Breast Cancer 2020; 6Article No. 3;:https://doi.org/10.1038/s41523-020-0145-3, E-pub

2019

Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial.

Denkert C, Budczies J, Regan MM, Loibl S, Dell’Orto P, von Minckwitz G, Mastropasqua MG, Solbach C, Thürlimann B, Mehta K, Blohmer JU, Colleoni M, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner BM, Dietel M, Fasching PA, Viale G. Breast Cancer Research and Treatment. 2019; 176(3):557-568, doi: 10.1007/s10549-018-05112-9, Journal

2018

When do patient reported quality of life indicators become prognostic in breast cancer?

Lee CK, Hudson M, Simes J, Ribi K, Bernhard J, Coates AS. Health Quality of Life Outcomes. 2018; 16(1):13 (epub 12 January 2018), DOI 10.1186/s12955-017-0834-2, Journal

2013

Prognostic significance of quality-of-life scores in early stage and relapsed breast cancer: results from seven randomized trials of the International Breast Cancer Study Group

Lee CK, Coates A, Hudson M, Ribi K, Bernhard J SABCS 2013 2013; Poster P6-08-04, Poster

Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: Results from International Breast Cancer Study Group Trials VIII and IX

Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, Gelber RD, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Cardoso F J Clin Oncol 2013; 31(25):3083-3090, E-pub

2012

Prognostic interaction between expression of p53 and estrogen receptor in patients with node negative breast cancer: Results from IBCSG Trials VIII and IX.

Coates AS, Miller EKA, O’Toole SA, Molloy TJ, Biale G, Goldhirsch A, Regan MM, Gelber RD, Sun Z, Castiglione-Gertsch M, Gusterson B, Musgrove EA, Sutherland RL. Breast Cancer Res. 2012; 14(6):R143: Abstract

LOAD MORE

Institutions